PR-39

• UNSPSC Description:

  PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice[1][2].

• Target Antigen:

  Bacterial; Proteasome

• Type:

  Peptides

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pr-39.html

• Solubility:

  H2O

• Smiles:

  O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N3[C@@H](CCC3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H](CC(C)C)C(N5[C@@H](CCC5)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(N[C@@H](CCCNC(N)=N)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N[C@@H](CC%10=CC=CC=C%10)C(N[C@@H](CC%11=CC=CC=C%11)C(N%12[C@@H](CCC%12)C(N%13[C@@H](CCC%13)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N%14[C@@H](CCC%14)C(N%15[C@@H](CCC%15)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(N%16[C@@H](CCC%16)C(N%17[C@@H](CCC%17)C(NCC(N[C@@H](CC%18=CC=CC=C%18)C(N%19[C@@H](CCC%19)C(N%20[C@@H](CCC%20)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC%21=CC=CC=C%21)C(N%22[C@@H](CCC%22)C(N%23[C@@H](CCC%23)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC%24=CC=CC=C%24)C(N%25[C@@H](CCC%25)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N

• Molecular Weight:

  4719.74

• References & Citations:

  [1]Maria Gaczynska, et al. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry. 2003 Jul 29;42(29):8663-70.|[2]Y Gao, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest. 2000 Aug;106(3):439-48.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  139637-11-9